Immune-related Adverse Events Associated With Checkpoint Inhibition in the Setting of CAR T Cell Therapy: A Case Series

Clin Lymphoma Myeloma Leuk. 2020 Mar;20(3):e118-e123. doi: 10.1016/j.clml.2019.12.014. Epub 2019 Dec 26.

¹ Division of Hematology/Oncology, Department of Medicine, University of California San Francisco Medical Center, San Francisco, CA; University of California San Francisco Helen Diller Family Comprehensive Center, San Francisco, CA. Electronic address: Swetha.Kambhampati@ucsf.edu.
² University of California San Francisco Helen Diller Family Comprehensive Center, San Francisco, CA.
³ Division of Hematology/Oncology, Department of Medicine, University of California San Francisco Medical Center, San Francisco, CA; University of California San Francisco Helen Diller Family Comprehensive Center, San Francisco, CA.
⁴ University of California San Francisco Helen Diller Family Comprehensive Center, San Francisco, CA; Department of Pharmacy, University of California San Francisco, San Francisco, CA.

No abstract available

Keywords: Cellular therapy; Checkpoint inhibitor; Diffuse large B cell lymphoma; Immune-related adverse events; Pembrolizumab.

Publication types